The plasma peptides of breast versus ovarian cancer
ConclusionThere was striking agreement between the breast cancer plasma peptides and proteins discovered by LC–ESI–MS/MS with previous biomarkers from tumors, cells lines or body fluids by genetic or biochemical methods. The results indicate that variation in plasma peptides from breast cancer versus ovarian cancer may be directly discovered by LC–ESI–M S/MS that will be a powerful tool for clinical research. It may be possible to use a battery of sensitive and robust linear quadrupole ion traps for random and independent sampling of plasma from a multisite clinical trial.
Source: Clinical Proteomics - Category: Biochemistry Source Type: research
More News: Alzheimer's | Biochemistry | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Clinical Trials | Genetics | Heart | Heart Attack | Multiple Sclerosis | Ovarian Cancer | Ovaries | Statistics